title: The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
abstract: Aromatase inhibitors (AIs) are widely prescribed for post-menopausal hormone receptor-positive breast cancer; however, musculoskeletal symptoms limit their tolerability. The purpose of this study was to determine whether joint pain in women receiving AIs is associated with inflammatory arthritis as measured by the disease activity score-28 (DAS-28), and to evaluate association with tenosynovitis on ultrasound. A total of 48 postmenopausal women with stage I-III breast cancer and hand pain were recruited from the Lombardi Comprehensive Cancer Center. Those receiving AIs were cases (n = 25), and those not receiving AIs were controls (n = 23). During a single study visit, subjects underwent blinded rheumatologic evaluation, DAS-28, health assessment questionnaires, autoantibodies, inflammatory markers, hand X-ray, and hand Duplex ultrasound. There were no significant differences between cases and controls in DAS-28, or inflammatory markers. A positive ANA (titer > 1:160) was found in ten patients, four of whom met criteria for autoimmune disease (two with rheumatoid arthritis and two with Sjogren's syndrome, equally distributed among cases and controls). This highlights the importance of considering underlying autoimmune disease in subjects with musculoskeletal complaints. Morning stiffness was more prolonged in women receiving AIs, but this did not reach statistical significance (P = 0.07). Ultrasound evidence of flexor tenosynovitis was common in both groups. Although tenosynovitis was not correlated with AI use (P = 0.26), there was a trend toward an association between tenosynovitis and morning stiffness (P = 0.089). While aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) were more common in subjects receiving AIs, they were not unique to AI users. There was no association between presence of AIMSS features and other chemotherapy or medication exposures. Although the majority of subjects had been using AIs for more than 6 months, this study did not find evidence for inflammatory arthritis in women with hand pain receiving AIs. Further studies are needed to develop a case definition of AIMSS, and to confirm whether these symptoms are attributable to AI use.
authors.affiliation: Division of Rheumatology, Immunology and Allergy, Georgetown University Hospital, 3800 Reservoir Road, Washington, DC, NW 20007, USA. vks4@gunet.georgetown.edu
authors.forename: Victoria K
authors.initials: VK
authors.lastname: Shanmugam
authors.forename: James
authors.initials: J
authors.lastname: McCloskey
authors.forename: Beth
authors.initials: B
authors.lastname: Elston
authors.forename: Sandra J
authors.initials: SJ
authors.lastname: Allison
authors.forename: Jennifer
authors.initials: J
authors.lastname: Eng-Wong
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000175:diagnosis*; D001168:Arthritis / Q000175:diagnosis; D001327:Autoimmune Diseases / Q000175:diagnosis; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000139:chemically induced / Q000175:diagnosis; D008875:Middle Aged; D009367:Neoplasm Staging; D010003:Osteoarthritis / Q000000981:diagnostic imaging; D017698:Postmenopause; D011859:Radiography; D013717:Tenosynovitis / Q000000981:diagnostic imaging; D014463:Ultrasonography
chemical_list: D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors
references.citation: J Clin Oncol. 2009 Oct 20;27(30):4955-60
references.pmid: 19752344
references.citation: Arthritis Rheum. 2005 Sep;52(9):2594-8
references.pmid: 16142740
references.citation: Cancer. 2009 Aug 15;115(16):3631-9
references.pmid: 19517460
references.citation: Lancet Oncol. 2008 Dec;9(12):1143-8
references.pmid: 18976959
references.citation: N Engl J Med. 2004 Mar 11;350(11):1081-92
references.pmid: 15014181
references.citation: Breast. 2007 Jun;16(3):223-34
references.pmid: 17368903
references.citation: Arthritis Rheum. 1988 Mar;31(3):315-24
references.pmid: 3358796
references.citation: Arthritis Rheum. 1997 Sep;40(9):1725
references.pmid: 9324032
references.citation: Br J Rheumatol. 1993 Jul;32(7):589-94
references.pmid: 8339131
references.citation: Arthritis Rheum. 1990 Nov;33(11):1601-10
references.pmid: 2242058
references.citation: J Clin Oncol. 2008 Feb 1;26(4):556-62
references.pmid: 18180462
references.citation: Clin Breast Cancer. 2010 Apr;10(2):144-7
references.pmid: 20299320
references.citation: Semin Oncol. 2003 Aug;30(4 Suppl 14):23-32
references.pmid: 14513434
references.citation: J Clin Oncol. 1993 Jun;11(6):1189-97
references.pmid: 8501505
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3797-9
references.pmid: 17761968
references.citation: Ann Rheum Dis. 2000 Apr;59(4):289-92
references.pmid: 10733476
references.citation: J Rheumatol. 1988 Feb;15(2):202-5
references.pmid: 3361530
references.citation: Br J Cancer. 2008 Dec 2;99(11):1763-8
references.pmid: 18985046
references.citation: Breast Cancer Res Treat. 2010 Aug;122(3):843-51
references.pmid: 20058066
references.citation: Breast Cancer Res Treat. 2008 Sep;111(2):365-72
references.pmid: 17922185
references.citation: J Clin Oncol. 2008 Jul 1;26(19):3147-52
references.pmid: 18474874
references.citation: Clin J Oncol Nurs. 2010 Jun;14(3):379-82
references.pmid: 20529801
references.citation: Lancet. 2002 Jun 22;359(9324):2131-9
references.pmid: 12090977
references.citation: Ann Rheum Dis. 2005 Nov;64(11):1582-7
references.pmid: 15860509
references.citation: J Rheumatol. 2007 Nov;34(11):2259-63
references.pmid: 17937464
references.citation: Arthritis Rheum. 1990 Feb;33(2):160-72
references.pmid: 2306288
references.citation: N Engl J Med. 2003 Nov 6;349(19):1793-802
references.pmid: 14551341
references.citation: J Rheumatol. 2001 Jul;28(7):1573-6
references.pmid: 11469464
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3877-83
references.pmid: 17761973
references.citation: J Clin Oncol. 2005 Jan 20;23(3):619-29
references.pmid: 15545664
references.citation: Ann Oncol. 2011 Aug;22(8):1763-9
references.pmid: 21273342
references.citation: Arthritis Rheum. 1991 Aug;34(8):1065-8
references.pmid: 1859483
references.citation: J Rheumatol. 2009 Sep;36(9):2061-6
references.pmid: 19738214
references.citation: Br J Cancer. 2010 Jul 27;103(3):291-6
references.pmid: 20606683
references.citation: Cancer. 2010 Sep 15;116(18):4360-7
references.pmid: 20549827
references.citation: Arthritis Rheum. 1986 May;29(5):577-85
references.pmid: 3718551
references.citation: Eur J Cancer. 2002 Oct;38(15):1984-6
references.pmid: 12376201
references.citation: J Rheumatol. 1997 Aug;24(8):1477-85
references.pmid: 9263138
references.citation: Lancet. 2005 Jan 1-7;365(9453):60-2
references.pmid: 15639680
references.citation: Bull NYU Hosp Jt Dis. 2008;66(3):216-23
references.pmid: 18937635
references.citation: J Clin Oncol. 2010 Aug 10;28(23):3784-96
references.pmid: 20625130
references.citation: Ann Rheum Dis. 2002 Jun;61(6):554-8
references.pmid: 12006334
references.citation: Cancer. 2007 Mar 1;109(5):832-9
references.pmid: 17243168
references.citation: J Rheumatol. 1999 Nov;26(11):2324-31
references.pmid: 10555885
references.citation: J Clin Endocrinol Metab. 2003 Dec;88(12):5951-6
references.pmid: 14671195
references.citation: Breast Cancer Res Treat. 2007 Jul;104(1):87-91
references.pmid: 17061044
references.citation: J Biol Chem. 2004 Nov 19;279(47):48487-90
references.pmid: 15337754
references.citation: Cancer Treat Rev. 2008 May;34(3):275-82
references.pmid: 18082328